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Monospeciﬁc and bispeciﬁc monoclonal SARSCoV-2 neutralizing antibodies that maintain
potency against B.1.617
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Min Zhao8, Tongqing Li 9,10, Therese Tripler4, Lupeng Ye 1,2,3, Ryan D. Chow 1,2,3,11,12, Zhenhao Fang1,2,3,
Chunxiang Wu 4, Matthew B. Dong1,2,3,6,11,13, Matthew Cook4, Guilin Wang14, Paul Clark1,2,3, Bryce Nelson9,10,
Daryl Klein 9,10, Richard Sutton8, Michael S. Diamond 7,15, Craig B. Wilen 5,6,21 ✉, Yong Xiong 4,21 ✉ &
Sidi Chen 1,2,3,12,13,16,17,18,19,21 ✉

COVID-19 pathogen SARS-CoV-2 has infected hundreds of millions and caused over 5 million
deaths to date. Although multiple vaccines are available, breakthrough infections occur
especially by emerging variants. Effective therapeutic options such as monoclonal antibodies
(mAbs) are still critical. Here, we report the development, cryo-EM structures, and functional
analyses of mAbs that potently neutralize SARS-CoV-2 variants of concern. By highthroughput single cell sequencing of B cells from spike receptor binding domain (RBD)
immunized animals, we identify two highly potent SARS-CoV-2 neutralizing mAb clones that
have single-digit nanomolar afﬁnity and low-picomolar avidity, and generate a bispeciﬁc
antibody. Lead antibodies show strong inhibitory activity against historical SARS-CoV-2 and
several emerging variants of concern. We solve several cryo-EM structures at ~3 Å resolution
of these neutralizing antibodies in complex with prefusion spike trimer ectodomain, and
reveal distinct epitopes, binding patterns, and conformations. The lead clones also show
potent efﬁcacy in vivo against authentic SARS-CoV-2 in both prophylactic and therapeutic
settings. We also generate and characterize a humanized antibody to facilitate translation
and drug development. The humanized clone also has strong potency against both the
original virus and the B.1.617.2 Delta variant. These mAbs expand the repertoire of therapeutics against SARS-CoV-2 and emerging variants.

A full list of author afﬁliations appears at the end of the paper.
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n the ongoing coronavirus disease 2019 (COVID-19) pandemic, severe acute respiratory syndrome coronavirus (SARSCoV-2) has infected over 270 million individuals, resulting in
more than 5 million deaths around the globe1. Although multiple
vaccines are available, breakthrough infections still occur2, especially with variant strains. Thus, broadly effective therapeutic
options are critical for medical treatment. Monoclonal antibodies
(mAbs) have been effectively deployed for the prevention or
treatment of COVID-193. However, the emergence of mutations
in spike4 and new variant lineages calls for developing additional
therapeutic interventions, including mAbs with potent and
broadly neutralizing ability.
Certain variants affect the rate of spread and/or even the ability
to evade immune recognition, potentially dampening the efﬁcacy
of antibody therapy or vaccines, and have been designated by
WHO and CDC as “variants of concern” (VoC)3. The B.1.1.7
lineage (Alpha variant) has an increased rate of transmission and
higher mortality5. The B.1.351 lineage (Beta variant) has an
increased rate of transmission, resistance to antibody therapeutics, and reduced vaccine efﬁcacy6–8. The lineage B.1.617
including B.1.617.1 (Kappa variant), B.1.617.2 (Delta variant),
and B.1.617.3 have emerged and become dominant in multiple
regions in the world9,10. The B.1.617 lineage has an increased rate
of transmission, shows reduced-serum antibody reactivity in
vaccinated individuals, and exhibits resistance to antibody therapeutics under emergency use authorization (EUA)11–15. The
Delta variant has become dominant in the United States and
many countries across the globe16–18. A newly emerged variant
Omicron (B.1.1.529) with extensive mutations in the Spike gene
also shows rapid transmission19–21. With these VOCs, even
emergency-use authorized (EUA) mAb therapies have faced
challenges with resistant viral variants, causing some to be
withdrawn, highlighting a need for more mAb candidates in
development. The Discovery of neutralizing antibodies with
broad neutralizing activities or multi-speciﬁc antibodies, which
can increase antibody efﬁcacy and prevent viral escape, might
improve the countermeasure arsenal against COVID-193.
The majority of preclinical and clinical SARS-CoV-2 mAbs
were discovered utilizing the blood of COVID-19 patients3. In
comparison, immunization of mice followed by hybridoma
screening is a standard method for discovering therapeutic mAbs
against viruses22. However, hybridoma screening for potent
neutralizing mAbs from immunized mice is a slow and laborious
process. The recent development of high-throughput single-cell
technologies enabled direct sequencing of fully recombined VDJ
sequences of B cell receptor (BCR) repertoires from single
cells23,24. This technology has successfully been used to isolate
human neutralizing mAbs against pathogens such as HIV, Ebola
viruses, and recently SARS-CoV-225–29.
The SARS-CoV-2 surface spike glycoprotein (S) mediates entry
into target cells and is a primary target of neutralizing
antibodies30–32. SARS-CoV-2 spike is a trimer in the pre-fusion
form, consisting of three copies of S1 and S2 subunits33,34. The
S1 subunit is composed of an N-terminal domain (NTD) and a
C-terminal receptor-binding domain (RBD) that recognizes the
host angiotensin-converting enzyme 2 (ACE2) receptor on the
cell surface31,35–37. The S2 subunit contains the fusion peptide,
along with other key regions, to induce membrane fusion of the
virus and the target cell38. Spike RBD is ﬂexible, moving between
“up” and “down” conformations but only binds to ACE2 in the
up conformation34,36,39. Previous studies have suggested that
most of the potent SARS-CoV-2 neutralizing antibodies target
spike RBD through an interface directly overlapping with the
ACE2-binding surface40,41.
Here, we report the rapid identiﬁcation of highly potent SARSCoV-2-neutralizing mAbs using high-throughput single-cell BCR
2

sequencing from mice immunized with puriﬁed SARS-CoV-2
RBD. We generate a bispeciﬁc antibody with two antigenrecognition variable regions from two of the top mAb clones
against SARS-CoV-2 RBD. These monospeciﬁc and bispeciﬁc
antibodies display high afﬁnity and avidity to the RBD-antigen,
and potently neutralized historical and B.1.617 lineage viruses.
We also generate and characterize a humanized antibody to
facilitate clinical development. This clone shows strong potency
against both the original virus and the Delta variant, both in vitro
and in vivo. We resolve the three-dimensional cryo-EM structures of these neutralizing antibodies in complex with the spikeectodomain trimer, which show the epitopes, as well as the
combinations of open and close RBD conformations of trimeric
spike, bound to the mAbs. Structure-based mutation and epitope
analysis reveal the neutralization potency of the lead mAb clones
against B.1.617 variants.
Results
Single-cell BCR sequencing of RBD-immunized mice identiﬁed
enriched BCRs encoding strong mAbs against SARS-CoV-2. To
generate potent and speciﬁc mAbs against SARS-CoV-2, we
immunized two different mouse strains: C57BL/6 J and BALB/c
with RBD protein with a C-terminal hexahistidine tag following a
standard 28-day immunized protocol (Supplementary Fig. 1a).
Using anti-mouse CD138 beads, we isolated progenitor B cells
and plasma B cells from spleen, lymph node, and bone marrow of
selected immunized mice that showed high serum binding titers
against RBD (Supplementary Fig. 1a). We performed single-cell
VDJ (scVDJ) sequencing on the isolated B cells (Supplementary
Fig. 1a). The scVDJ data revealed the landscape of immunoglobulin clonotypes in immunized mice (Fig. 1a and Supplementary
Dataset 1) and identiﬁed enriched IgG1 clones (Fig. 1b and
Supplementary Dataset 1). We took the VDJ sequences from 11
top-ranked clones by clonal frequency. We then cloned the paired
variable region of the heavy and light chain into human IgG1
(hIgG1) heavy and light chain backbone vectors separately, for
antibody reconstruction utilizing the Expi293F mammalian
expression system.
Anti-Spike RBD monoclonal antibodies have single-digit
nanomolar afﬁnity and low-picomolar avidity. After expression and puriﬁcation of hIgG1 antibody clones, we tested their
reactivity against SARS-CoV-2 spike RBD by ELISA. Eight of the
eleven mAbs showed positive RBD-binding (Supplementary
Fig. 1c). We then screened mAb clones showing a high RBD
ELISA positive rate for their neutralizing ability using an HIV-1based SARS-CoV-2 pseudovirus system and a VSV-based SARSCoV-2 pseudovirus system (Supplementary Fig. 2a–c). Two
mAbs, Clones 2 and 6, showed the strongest binding and neutralizing activity (Supplementary Fig. 2a–c). As SARS-CoV-2
continues to mutate and evolve, leading to variants, it is critical to
prevent viral escape from antibody recognition. To overcome this
problem, antibody combinations from two or more mAbs have
been developed and utilized42. As an alternative, a single bispeciﬁc mAb can be used, as it can recognize two epitopes. One
advantage of bispeciﬁc mAbs is that a single antibody product can
be manufactured instead of two separate mAbs, which in theory
could reduce the cost and formulation complexity. Thus, we
generated a bispeciﬁc antibody using the antigen-speciﬁc variable
regions of both Clones 2 and 6 (named as Clone 16). To generate
the bispeciﬁc antibody, we utilized a “knobs into holes” (KiH)CrossMab methodology, and to ensure the correct heterodimerization of the two different heavy chains and correct pairing
of heavy and light chains of each variable region (Supplementary
Fig. 1d). We validated the antigen-speciﬁcity of the bispeciﬁc
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Fig. 1 Immunization-single B cell sequencing leads to development of potent monoclonal antibodies in both monospeciﬁc and bispeciﬁc forms.
a Frequency distribution of immunoglobulin isotypes in SARS-CoV-2 Spike RBD (receptor-binding domain) immunized mice. (Top) Analysis of isotypes in
both bone marrow and spleen in RBD-immunized C57BL/6 J mice (n = 1 mouse) (Bottom) Analysis of isotypes in RBD-immunized C57BL/6 J and BALB/c
mice (n = 1 mouse). b CDR3 sequences of heavy and light chains of the top enriched antibody clones from RBD-his tag immunized C57BL/6 J mice (Top)
and BALB/c mice (Bottom). CDR3: Complementarity-determining regions 3. c Octet measurement of binding strengths top SARS-CoV-2 RBD-speciﬁc
monospeciﬁc mAb clones (Clones 2 and 6). The binding was particularly strong, thus that the dissociation stage was never observed in this BLI assay.
d SPR measurement of binding strengths top SARS-CoV-2 RBD-speciﬁc monospeciﬁc mAb clones (Clones 2 and 6), using an NTA chip where the antigen
(RBD) was ﬁxed on the chip. e SPR measurement of binding strengths top SARS-CoV-2 RBD-speciﬁc monospeciﬁc mAb clones (Clones 2 and 6), a
humanized mAb clone (Clone 13), and a bispeciﬁc mAb (Clone 16), using an Fc chip where antibodies were ﬁxed on the chip. Source data and additional
statistics for experiments are provided as a Source Data ﬁle.

antibody along with its two parent mAbs using ELISA (Supplementary Fig. 1e).
To characterize the biophysical nature of the RBD reactivity of
lead clones, we performed biolayer interferometry (BLI) and
surface plasmon resonance (SPR) (Fig. 1c–e). BLI results showed
that Clones 2 and 6 bound to the RBD with picomolar level
dissociation constant (Kd) (Fig. 1f). The binding is particularly
strong so that the dissociation stage was never observed in the BLI
assay (Fig. 1c). SPR using an NTA-CHIP based assay with the
RBD-antigen immobilized also revealed picomolar level dissociation constant (Kd) for Clones 2 and 6 (Fig. 1d). In the NTACHIP, where the RBD-antigen is immobilized, multiple binding
events can occur, leading to potential trimer formation of RBD
protein and measurement of avidity. In parallel, we performed
SPR with a CM5 CHIP-based assay with pre-coated antibodies,
which measures monovalent binding between RBD and the
antibody. Results from the CM5 CHIP SPR assay revealed a
strong afﬁnity with single-digit nanomolar Kd of Clone 2 and
Clone 6 (Fig. 1e). A humanized Clone 2 (named Clone 13)
maintained a strong binding afﬁnity to RBD at low-double-digit
nanomolar Kd (Fig. 1e). The bispeciﬁc Clone 16 also displayed

high afﬁnity to RBD also at single-digit nanomolar Kd (Fig. 1e),
although not signiﬁcantly higher than either parental clone alone.
Cryo-EM structures of lead antibody clones bound to the
SARS-CoV-2 spike deﬁne epitopes and binding conformations.
We then generated Fab fragments of the lead clones and determined the cryo-EM structures of Clone 2 or 6 Fabs in complex
with the ectodomain of SARS-CoV-2 spike trimer (S trimer) at
~3 Å resolution (Table 1). In both cases, an S trimer is bound
with three Fab molecules, one per RBD in various conformations.
In total, we determined ﬁve different Fab-S trimer complex
structures, each with the S trimer in a speciﬁc conformational
state. Clone 2 Fab binds to S trimer in two states, one with 2
RBDs in the up conformation (60% of all complexes) and one
with all 3 RBDs up (40%) (Fig. 2a and Supplementary Fig. 3a).
Clone 6 Fab binds to S trimer in three states, one with all three
RBDs down (26% of all complexes), one with 1 RBD up (43%)
and one with two RBDs up (31%) (Fig. 2b and Supplementary
Fig. 3b). Thus, Clones 2 and 6 Fab molecules are capable
of recognizing SARS-CoV-2 S trimer in all possible RBD
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Table 1 Cryo-EM data collection and reﬁnement statistics.

Data collection and
processing
Magniﬁcation
Voltage (kV)
Electron exposure (e–/Å2)
Defocus range (μm)
Pixel size (Å)
Symmetry imposed
Initial particle images (no.)
Final particle images (no.)
Map resolution (Å) FSC
threshold
Reﬁnement
Map sharpening B factor
(Å2)
Model map FSC (masked)
Model composition
Non-hydrogen atoms
Protein residues
Ligands
B factors (Å2)
Protein
Ligand
R.m.s. deviations
Bond lengths (Å)
Bond angles (°)
Validation
MolProbity score
Clashscore
Poor rotamers (%)
Ramachandran plot
Favored (%)
Allowed (%)
Disallowed (%)

3dSpike-Fab6 (PDB
7MW2) (EMD24060)

2dSpike-Fab6 (PDB
7MW3) (EMD24061)

1dSpike-Fab6 (PDB
7MW4) (EMD24062)

2uSpike-Fab2 (PDB
7MW5) (EMD24063)

3uSpike-Fab2 (PDB
7MW6) (EMD24064)

81,000
300
66.5
−0.8 to −1.8
1.068
C3
655318
68416
2.97

81,000
300
66.5
−0.8 to −1.8
1.068
C1

81,000
300
66.5
−0.8 to −1.8
1.068
C1

81,000
300
66.5
−0.8 to −1.8
1.068
C1

111449
3.15

80954
3.42

81,000
300
66.5
−0.8 to −1.8
1.068
C1
1013040
135336
3.42

−81 to −91

−69 to −127

−76 to −142

−74 to −189

−80 to −100

0.83

0.81

0.74

0.67

0.69

33,807
4293
72

33,825
4293
72

33,741
4290
74

33,661
4245
83

35,247
4446
87

41
80

46
69

63
94

118
156

39
62

0.003
0.6

0.003
0.6

0.003
0.6

0.003
0.7

0.004
0.8

1.6
7.1
0.08

1.7
7.5
0.08

1.8
8.7
0.11

2.2
14.1
0.08

2.0
11.0
0.11

96.68
3.15
0.17

96.09
3.55
0.36

95.64
4.15
0.21

91.39
8.03
0.57

94.27
5.06
0.66

181380
3.22

3dSpike-Fab6 Spike trimer with three RBDs down in complex with Fab clone 6, 2dSpike-Fab6 Spike trimer with two RBDs down in complex with Fab clone 6, 1dSpike-Fab6 Spike trimer with one RBD down in
complex with Fab clone 6, 2uSpike-Fab2 Spike trimer with two RBDs up in complex with Fab clone 2, 3uSpike-Fab2 Spike trimer with three RBDs up in complex with Fab clone 2.

conformations, potentially reducing viral immune evasion when
used in combination or as a bispeciﬁc. Within each clone, the
same Fab-RBD-binding interface is maintained regardless of the
RBD conformations across all S trimer states. Between the two
clones, the Fab-RBD interfaces are different, although the two Fab
clones bind RBD in similar locations with RBD adopting virtually
the same conformation (RMSD 0.46 Å) (Fig. 3a, b). Clone 2 Fab-S
trimer complexes appear more ﬂexible than Clone 6 complexes,
as indicated by less well-deﬁned cryo-EM density in the Clone 2
Fab-RBD regions.
Besides the major Fab-RBD interfaces described above, in the
Clone 6 Fab complexes with two or three RBDs down, a downRBD-binding Fab makes an additional contact to a side surface of
an adjacent down-RBD to lock both RBDs in the closed
conformation incompetent in ACE2 recognition (Supplementary
Fig. 4d left two panels), which may provide a second neutralization mechanism. The additional contact is achieved by the
CDRL1 loop of Clone 6 Fab that protrudes in between the two
neighboring down-RBDs (Supplementary Fig. 4c), along with the
framework region 3 (FWR3) of the Fab that interacts with a
nearby side surface of the adjacent down-RBD (Supplementary
Fig. 4d, left two panels). In addition, in all complexes with two
up/one down-RBDs and the Clone 6 Fab complex with two
down/one up-RBDs, a down-RBD-binding Fab contacts the side
surface of an adjacent up-RBD through another conserved
4

interface mainly involving the CDRL1 loop of the Fabs
(Supplementary Fig. 4b, d, right panels), further stabilizing the
conformation of the adjacent up-RBDs. These types of bivalent
interactions are not observed for the up-RBD-binding Fabs.
Clone 2 and Clone 6 Fabs interact with spike RBD at similar
locations, as both directly block access of the host receptor ACE2
(Fig. 3a). Clone 6 Fab shields the entire top surface of spike RBD
(both “left shoulders” and “right ridge”), whereas Clone 2 Fab has
a relative rotation of ~17° pivoted on the RBD right ridge,
resulting in a larger contact area there and less contact with the
RBD left shoulder (Fig. 3b). When overlaying a Clone 2 Fabbound down-RBD onto a Clone 6 Fab-bound down-RBD in the S
trimer with more than one RBDs down, spatial clashes are
detected between the Clone 2 Fab and the neighboring down RBD
(Supplementary Fig. 4a). This also explains why we did not
observe Clone 2 Fab-bound S trimer in a conformation state with
more than one RBD down. In each case, all six complementaritydetermining regions (CDRs) of the Fab participate in RBD
interactions (Fig. 3c). The three CDRH loops of the two clones
share similar overall conformations and interact mainly with the
right ridge of spike RBD (Fig. 3c, upper panel). The three CDRH
loops of Clone 2 Fab form a large positively charged paratope,
complementing a negatively charged epitope contributed by the
right ridge of spike RBD (Supplementary Fig. 5a, upper panels).
The three CDRH loops of Clone 6 Fab engage spike RBD
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Fig. 2 Cryo-EM structures of the ectodomain of SARS-CoV-2 spike trimer in complex with Clone 2 or Clone 6 Fab and Structural comparisons.
a, b Cryo-EM structures of the ectodomain of SARS-CoV-2 spike trimer in complex with Clone 2 (a) or Clone 6 (b). Each Fab molecule is shown as ribbons
in different colors, spike RBD is shown as dark gray ribbons, with the rest of spike trimer shown as gray surface. The particle distribution of each S trimer
conformation is shown correspondingly.

predominantly through hydrophobic interactions (Supplementary Fig. 5b, upper left), with the CDRH3 loop also engaging RBD
through modest electrostatic interactions (Supplementary Fig. 5b,
upper right).
In contrast to the relatively conserved binding locations by the
CDRH loops, the three CDRL loops of Clones 2 and 6 diverge in
RBD-binding paratopes (Fig. 3c, lower panel). CDRL1 and
CDRL3 of Clone 2 Fab primarily contact the epitopes at RBD
right ridge and the CDRL2 loop engages RBD central groove,

whereas CDRL3, CDRL1, and CDRL2 of Clone 6 Fab complement with the RBD right ridge, central groove, and left shoulder,
respectively, together covering the top surface of the RBD. Both
Clones 2 and 6 Fab CDRL loops contact spike RBD primarily
through hydrophobic interactions along with modest electrostatic
interactions (Supplementary Fig. 5a, b, lower panels). A comparison of the Clone 2 and Clone 6 Fabs revealed that the most
different region comes from the CDRH3 loop (Fig. 3d). The
Clone 6 Fab contains a longer CDRH3 loop, which inserts into
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Fig. 3 Binding interfaces and epitopes of lead monoclonal antibodies. a Overlay of the structures of spike RBD from its complex with the host ACE2
receptor, Clone 2 or Clone 6 Fab indicates both antibody clones directly block the ACE2 access. b Overlay of the structures of spike RBD from its complex
with Clone 2 or Clone 6 Fab reveals a 17° rotation pivoted at the right ridge of spike RBD, resulting in less contact of Clone 2 Fab light chain with the left
shoulder of spike RBD. The comparison of the Clone 2 and Clone 6 Fab binding interfaces with spike RBD is shown in the bottom parallel insets. The
nomenclature of the top surface of spike RBD is described in the top inset. c The orientations of the three CDRH (upper panel) and CDRL (lower panel)
loops of Clone 2 or Clone 6 Fabs on spike RBD. The structures were overlaid with the RBD potions. d Left, overlay of Clone 2 and Clone 6 Fab molecules
alone. The CDRH3 loops that have the largest conformational difference are highlighted in brighter colors (blue for clone 2 and red for clone 6). Lower
inset, amino acid sequence alignment of the CDRH3 loops of both clones. Right, spike RBD residue F486, which is shown as orange sticks, has a large
conformational change upon RBD-binding to the two clones. e Comparison of spike RBD epitope regions for Clone 2 and Clone 6 Fabs, highlighted in cyan
and magenta, respectively. The spike binding interface for the hACE2 receptor is highlighted in yellow.

the central groove of spike RBD to generate a tighter engagement.
As a consequence, this induces a substantial change in the RBD,
which otherwise maintained a nearly identical conformation,
where residue F486 ﬂips to contact the CDRL3 loop of Clone 6
instead of interacting with the CDRH3 loop of Clone 2 (Fig. 3d).
Even though the two Fabs interact with the RBD with similar
buried surface areas (949 Å2 in Clone 2 vs. 894 Å2 in Clone 6), the
6

further spread-out RBD-binding mode of Clone 6 Fab is more
similar to that of the host ACE2 receptor (Fig. 3e).
Multiple mAbs have been generated to date and are in various
stages of research and development, with some granted EUA for
clinical use3,28,43–45. We compared our structures to several of the
previously published mAb:Spike structures, and found that the
RBD-binding modes of Clone 2 and Clone 6 Fabs differ from
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these SARS-CoV-2 neutralizing antibodies reported in the
primary literature and the protein databank (PDB). Three
previously reported antibodies (2H2, CV05-163, and S2H13)
target the spike RBD in somewhat similar orientations but with
substantial rotations or shifts46–48 (Supplementary Fig. 6a).
Another two reported antibodies (CT-P59 and BD23) adopt
RBD-binding conformations resembling those of Clone 2 and 6
Fabs27,49, however, the binding positions of heavy chains and
light chains are exchanged (Supplementary Fig. 6b).
Lead antibody clones potently neutralize SARS-CoV-2
WA1 and B.1.617 variant. We next tested the neutralization
ability of the monospeciﬁc and bispeciﬁc clones. Because spike
protein can mediate receptor-mediated membrane fusion50,
we utilized a cell fusion assay in which expression of Wuhan-1/
WA1 SARS-CoV-2 spike on one cell can induce fusion
with hACE2-expressing cells. All three antibodies (Clone 2, Clone
6, and Clone 16) effectively inhibited this spike-mediated cell
fusion activity (Supplementary Fig. 2d, e). Next, we used an
HIV-1-based pseudovirus system pseudotyped with SARS-CoV-2
Wuhan-1/WA1, B.1.351, and B.1.617 to evaluate the neutralization potential of these mAbs. All three antibodies (Clone 2,
Clone 6, and Clone 16) potently inhibited SARS-CoV-2-Wuhan-1
pseudovirus with low ng/mL level IC50 values (Fig. 4a). Due to
the partial overlap in the binding domains in RBD, the
bispeciﬁc Clone 16 was not stronger than either Clone 2 or
Clone 6. These three antibodies also inhibited B.1.351 SARSCoV-2 pseudovirus, with somewhat reduced potency (higher level
of IC50 values, mid ng/mL for Clones 2/6, and high ng/mL for
Clone 16) (Fig. 4b). In comparison, all three antibodies maintained potent neutralizing activity against the B.1.617
pseudovirus, with sub-single-digit to low-single-digit ng/mL level
IC50 values (Fig. 4c). We also performed these experiments
with Clones 2 and 6 as a cocktail combination (Fig. 4d–f).
Although the combination is not superior to the single clone
alone, the results again conﬁrmed the potency of both Clones 2
and 6 as the single agents, where both clones showed strong
potency against Wuhan-1/WA1 spike and B.1.617 pseudoviruses
(single-digit ng/mL IC50) and slightly reduced potency against
B.1.351 (Fig. 4d–f).
Epitope and mutation analysis of the mAb:RBD structures on
the binding interface between the lead mAbs and hotspot
mutations in Beta and Delta variants. To evaluate the structural
impacts of the RBD mutations on the binding of the Beta and
Delta variants, we used our Spike:mAb Cryo-EM structures and
generated homology models of the two variants (Fig. 4g). The
Beta variant encodes three mutations (K417N, E484K, and
N501Y) in spike RBD. Although N501 is not located within the
epitope region, the Y501 mutation may have weak interactions
with the CDRL2 loop of both Fab clones (Fig. 4g, lower left).
K417 has no contact with Clone 2 Fab, but interacts with the
CDRL1 loop of Clone 6 Fab, and the K417N mutation would
likely abolish this interaction (Fig. 4g, lower left). E484, which is
located on top of the RBD right ridge, is targeted by the CDRH1
and CDRH3 loops of both Fab clones and has a larger contact
area on Clone 6 Fab (Fig. 4g, upper left). The Delta variant
encodes an E484Q at the position, which likely results in less
disruption of its interaction with the Fabs (Fig. 4g, upper right).
The two other mutation sites, L452 and T478, are not located
within the antibody-binding surface (Fig. 4g, right). However, the
T478K mutation is located close to the interface, especially that
with Clone 2 Fab, and could affect RBD recognition by both
clones (Fig. 4g, lower right).

ARTICLE

In vivo prophylactic and therapeutic efﬁcacy of the lead mAbs
against authentic SARS-CoV-2 virus. We next evaluated the
potency of the lead antibodies against authentic SARS-CoV-2
(WA1/2020) infection. All three antibodies (Clone 2, Clone 6, and
the bispeciﬁc Clone 16) inhibited infection of SARS-CoV-2 WA1/
2020 (low-mid ng/mL level IC50s) (Fig. 5a). We then assessed the
efﬁcacy of mAbs against SARS-CoV-2 in vivo, when administered
as either pre-exposure prophylaxis or postexposure therapy
(Fig. 5b). We performed protection studies with SARS-CoV-2
using K18-hACE2 transgenic mice51–53. We challenged K18hACE2 mice with 2 × 103 plaque-forming units (PFU) of the
SARS-CoV-2 WA1/2020 virus (Fig. 5b). The hACE2 transgenic
mice were randomly divided into three groups, and mice in each
group were injected with 20 mg/kg of Clone 2 mAb, Clone 6
mAb, or placebo control; with the treatment given as a single dose
either 24 h before or 18 h after viral infection (Fig. 5b).
In the prophylactic setting, all (8/8, 100%) mice in the placebo
group developed a severe disease due to viral challenge, and most
(7/8, 87.5%) of them lost substantial body weight and succumbed
from the disease, with only one mouse recovering weight
(Fig. 5c–e). In contrast, all mice receiving treatment of either
Clone 2 (8/8, 100%) or Clone 6 (7/7, 100%) maintained their
body weight throughout the duration of the study and survived
SARS-CoV-2 infection (Fig. 5c–e). In the therapeutic setting, all
(5/5, 100%) mice in the placebo group developed the severe
disease, and most (4/5, 80%) of them lost body weight (Fig. 5f–h).
In contrast, all mice treated with Clone 2 (5/5, 100%) or Clone 6
(5/5, 100%) at +18 h maintained their body weight and survived
the viral infection with no signs of disease (Fig. 5f–h). These data
suggested that these mAbs can protect the animals from lethal
SARS-CoV-2 infection in either prophylactic or therapeutic
settings.
Generation, biophysical characterization, and functional testing of a humanized mAb clone. To improve clinical translatability, we also developed a humanized Clone 2, using standard
antibody humanization approaches with framework humanization and engineered mutations, based on canonical human antibody backbone sequences as well as the antibody: RBD Cryo-EM
structures (Methods). A resultant humanized clone that maintains RBD speciﬁcity was generated (Clone 13 A) (Fig. 6a). We
puriﬁed Clone 13 A with other lead clones for characterization
and functional studies (Fig. 6b). BLI data showed that Clone 13 A
has a low-double-digit Kd value (Fig. 6c).
Clone 13 A also potently neutralized WT/WA1 and B.1.617
pseudoviruses (single-digit ng/mL IC50) (Fig. 6d). We also
performed authentic virus neutralization assays with Clone 13 A,
along with Clone 2, Clone 6, and two EUA antibodies (RGEN
10933 and 10987). Clones 2, 6, and 13 A all potently neutralized
SARS-CoV-2 WA1/2020 and Delta variant authentic viruses
(Fig. 6e). Against Delta variant, RGEN 10933 has a 1.6× drop in
potency, Clone 13 A has a 2× drop, Clone 2 has a 4× drop, Clone 6
has an 18× drop, while RGEN-10987 has a 52× drop.
We also performed in vivo challenge experiment with Clone
13 A using authentic viruses (Fig. 6f–h). Similar to the prior
results all (8/8, 100%) mice in the placebo group developed a
severe disease due and succumbed from infection (Fig. 6f, h). In
contrast, all mice receiving Clone 13 A (9/9, 100%) maintained
body weight throughout the duration of the study and survived
from SARS-CoV-2 WA1 infection (Fig. 6g, h). We also tested
Clone 13 A against the Delta variant authentic virus challenge. All
(8/8, 100%) mice in the placebo group developed a severe disease
due and succumbed from infection (Fig. 6i). In contrast, all mice
receiving Clone 13 A (8/8, 100%) maintained body weight
throughout the duration of the study (Fig. 6j). Of note, the Delta
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virus appeared to be not lethal for hACE2 mice within the
experimental setting, thus the survival beneﬁt can not be
measured against Delta. These data conﬁrmed that the humanized Clone 13 A maintained its potency and protective activity
in vivo against authentic SARS-CoV-2, both the original WA1
and Delta variant in the B.1.617 lineage.
8

Discussion
The ongoing COVID-19 pandemic and the continued emergence
of SARS-CoV-2 variants have necessitated the rapid development
of therapeutic interventions. The discovery and development of
neutralizing antibodies with expanding collections of epitopes are
critical to provide countermeasure options against escape seen
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Fig. 4 Lead mAb clones showed strong neutralization potency against WT/WA1 and B.1.617, with epitope and mutation analysis of the Fab-spike RBD
interfaces. a Neutralization assay on top mAb clones using WT/WA1 SARS-CoV-2 Spike pseudotyped HIV-1-lentivirus carrying an EGFP reporter
(pseudovirus). Data were presented as mean values ± SEM, n = 3 biological replicates. b Neutralization assay on top mAb clones using B.1.351 variant
SARS-CoV-2 Spike pseudovirus. Data were presented as mean values ± SEM, n = 3 biological replicates. c Neutralization assay on top mAb clones using
B.1.617 variant SARS-CoV-2 Spike pseudovirus. Data were presented as mean values ± SEM, n = 3 biological replicates. d Neutralization assay on top mAb
clones and their combination using WT/WA1 SARS-CoV-2 Spike pseudovirus. Data were presented as mean values ± SEM, n = 3 biological replicates.
e Neutralization assay on top mAb clones and their combination using B.1.351 variant SARS-CoV-2 Spike pseudovirus. Data were presented as mean
values ± SEM, n = 3 biological replicates. f Neutralization assay on top mAb clones and their combination using B.1.617 variant SARS-CoV-2 Spike
pseudovirus. Data were presented as mean values ± SEM, n = 3 biological replicates. g Structural analysis of the spike RBD mutations from the B.1.351 (left
panels) and B.1.617 (right panels) variants at the interfaces with Clone 2 and Clone 6 Fabs. The residues mutated in spike RBD are shown as gray sticks in
wild-type (WT) spike and yellow in the B.1.351 variant and green in the B.1.617 variant. Another frequent RBD mutation S477N in SARS-CoV-2 strains is
also shown as slate sticks. The spike RBD is shown as a light gray ribbon, and the CDR loops of Clone 2 and Clone 6 Fabs are shown as cyan and magenta
ribbons, respectively, with the WT RBD-interacting residues, highlighted in brighter blue and red colors. Source data and additional statistics for
experiments are provided as a Source Data ﬁle.

with emerging variants of concern. We combined SARS-CoV-2
Spike RBD protein immunization with high-throughput singlecell BCR sequencing technology to establish a platform to develop
neutralizing antibody candidates. We identiﬁed two highly potent
and speciﬁc SARS-CoV-2 neutralizing mAb clones with singledigit nanomolar afﬁnity and low-picomolar avidity. We also
generated a bispeciﬁc antibody of these two lead clones, as well as
a potent humanized clone. The lead antibodies showed strong
neutralization ability against SARS-CoV-2 and the highly transmissible B.1.617 lineage that poses a risk of reducing the efﬁcacy
of currently available therapeutic antibodies and prophylactic
vaccines.
The SARS-CoV-2 spike protein is dynamic, and three conformations of spike pre-fusion trimers have been detected on
intact virions: all RBDs down, 1 RBD up, and 2 RBDs up, with the
last one only existing in vitro with multiple stabilizing
mutations54. The spike RBD needs to extend upwards to be
accessible to ACE2, and the presence of host ACE2 changes the
population distribution of different spike conformations by promoting the RBD towards the up/open state favorable for ACE2
binding55. Genetic variations in spike can also change the conformational equilibrium of the trimer, subsequently affecting
virus infectivity56. Although antibody therapy has been developing rapidly to prevent or treat SARS-CoV-2, infection, the
precise determinants of neutralization potency remain unclear. In
addition to direct receptor blockade by antibody binding, modulation of spike-mediated membrane fusion by altering the
ACE2-triggered spike protein conformational cycle has been
suggested as another determinant of the antibody neutralization
potency50.
Depending on the binding mode, some antibodies may facilitate the spike conformational cycle to the ﬁnal stage with all
three RBDs open, or locking the spike trimer in a pre-fusion state,
therefore enhancing or inhibiting the cell membrane fusion and
syncytium formation. Based on our cryo-EM analysis, Clone 6
Fab binds to spike trimer preferentially with at least one RBD
down and effectively skews the spike trimer towards pre-fusion
states (Fig. 2b). Besides making two neighboring down-RBDs
inaccessible for ACE2 binding (Supplementary Fig. 4c, d, left
panels), a down-RBD-binding Clone 6 Fab can also interact with
an adjacent up-RBD through a quaternary epitope located at the
sidewall of the up-RBD (Supplementary Fig. 4d, right), which
clashes with ACE2 binding (Supplementary Fig. 4e, right),
thereby directly blocking ACE2 access to two RBDs simultaneously. This bipartite binding mode presumably is more stable
than the single binding mode with the up-RBD alone, explaining
why no spike trimer with all three RBDs open was detected when
complexed with Clone 6 Fab. We hypothesize that the Clone 6
Fab binding to this secondary epitope of RBD helps lock the spike

trimer in the pre-fusion form, which inhibits the spike-mediated
cell membrane fusion by historical virus and even the B.1.1.7
variant that has enhanced binding afﬁnity to ACE257 (Supplementary Fig. 2d, e, middle). In contrast, due to the different
binding conformations of Clone 2 Fab on spike RBD, the spike
trimer has been detected in skewed states that favorite RBDs up
(Fig. 2a), which mimics the effect of ACE2 binding during the
conformational cycle of the spike trimer. Nonetheless, we found
that Clone 2 Fab also efﬁciently suppresses spike-mediated cellcell fusion50 (Supplementary Fig. 2d, e, left), suggesting that the
mechanism determining the neutralization potency of spiketargeting antibodies is complex.
Antibody resistance of SARS-CoV-2 B.1.1.7, B.1.351, and
B.1.617 lineage variants has been reported7,14,58. The B.1.1.7
variant of the SARS-CoV-2 spike contains a single mutation
(N501Y) in the RBD, which has been reported to enhance the
spike RBD-ACE2 binding afﬁnity that could disfavor antibody
neutralizations competing with ACE2 for RBD-binding57. N501
does not directly interact with either Clone 2 or Clone 6 Fab,
although the mutation may generate allosteric effects on other
CDRL loops nearby to disrupt the binding interface57. While the
B.1.1.7 variant spreads faster, has a higher case-fatality rate, and
has some antibody resistance, it does not reduce the efﬁcacy of
the currently approved vaccines7,59–61. In contrast, the B.1.1.351
variant of SARS-CoV-2 showed an increased rate of transmission,
resistance to antibody therapeutics, and reduced vaccine
efﬁcacy6–8,60. In addition to the N501Y mutation, the B.1.351
variant has two additional point mutations K417N and E484K in
spike RBD, which perturbs the RBD epitope recognition by both
antibody clones, explaining their reduced potencies against the
B.1.351 variant. The lineage B.1.617 has mutations in spike
including G142D, E154K, L452R, E484Q, D614G, P681R, and
Q1071H15, which could affect a number of leading therapeutic
antibodies tested to date14,62,63. The L452R variant evades cellular
immunity and increases infectivity64. L452R and S477N might
affect the potency of Clones 2 and 6 to some degree based on the
structure.
Several therapeutic antibodies have been granted EUA for
clinical use by the FDA, such as two from Regeneron developed
in a previous study65. Recent studies showed that some of the
EUA mAbs have a signiﬁcant reduction in neutralization activities against B.1.617 lineage variants14,62. Many antibodies have
been developed by the ﬁeld and tested against various
VoCs63,66,67. Our data also showed that RGEN-10987 has substantially diminished potency against Delta. To better understand
the impact of Delta mutations on antibody neutralization
potency, we performed structurally; analysis with the Delta RBD
(Supplementary Fig. 8). The epitopes of REGN-10987 centered
around the RBD left shoulder loop on the β1 end, which hereafter
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we termed left shoulder loop 1 (Supplementary Fig. 8). Clone 2
primarily targets a region at the right ridge of RBD. The L452R
mutation of Delta is on the C-terminus edge of the left shoulder
loop 1 and is critical for the loop 1 conformation. L452R is
observed to favor an orientation interacting with the Y351 and is
likely to disrupt the original conformation of left should loop 1,
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consistent with the reduction of the afﬁnity and potency of the
REGN-10987 antibody. The E484Q, on the other hand, was not
observed to signiﬁcantly change side-chain orientation and is less
likely to cause drastic conformational changes on nearby loops.
The mutation-induced side-chain orientation, as well as nearby
loop conformation change plus distinct antibody targeting
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Fig. 5 Lead monoclonal antibodies have potent prophylactic and therapeutic in vivo efﬁcacy against replication-competent SARS-CoV-2 virus. a In
vitro neutralization of top mAb clones against authentic SARS-CoV-2 in BL3 setting, n = 3 biological replicates. b Schematics of in vivo efﬁcacy testing of
top mAb clones against lethal challenges of authentic SARS-CoV-2 in hACE2 transgenic mice at BL3 level, in both prophylactic (upper panel) and
therapeutic (bottom panel) settings. c–e Prophylactic efﬁcacy testing. c, d Body weight curves of antibody and placebo (DPBS) treated hACE2 transgenic
mice under lethal challenges of authentic SARS-CoV-2. c Spider curves of body weight changes of individual mouse plotted separated by group.
d Mean ± SEM curves of body weight changes. (Clone 2, n = 8; Clone 6, n = 7, and DPBS, n = 8 mice, respectively), Clone 2 vs DPBS: p < 0.0001, Clone 6
vs DPBS: p < 0.0001. e Survival curves of antibody and placebo (DPBS) treated hACE2 transgenic mice under lethal challenges of authentic SARS-CoV-2
(the same experiment in c, d), a two-sided statistical test was used to assess statistical signiﬁcance. Therapeutic efﬁcacy testing. f–h Body weight curves of
antibody and placebo (isotype hIgG1) treated hACE2 transgenic mice under lethal challenges of authentic SARS-CoV-2. f Spider curves of body weight
changes of individual mouse plotted separated by group. g Mean ± SEM curves of body weight changes. (Clone 2, n = 5; Clone 6, n = 5, and hIgG1, n = 5
mice, respectively), Clone 2 vs hIgG1: p < 0.0001, Clone 6 vs hIgG1: p < 0.0001. h Survival curves of antibody and placebo (hIgG1) treated hACE2
transgenic mice under lethal challenges of authentic SARS-CoV-2 (the same experiment in f, g), a two-sided statistical test was used to assess statistical
signiﬁcance. In this ﬁgure: Data were shown as mean ± s.e.m. plus individual data points in dot plots. Statistics: Two-way ANOVA was used to assess
statistical signiﬁcance for multi-group curve comparisons; Log-rank test was used to assess statistical signiﬁcance for survival curve comparisons; unless
otherwise noted. The p values are indicated in the plots. Source data and additional statistics for experiments are as a Source Data ﬁle.

epitopes, are consistent with the observation that Clone 2 retained
its neutralization potency against Delta, whereas REGN-10987
did not.
Here, we show, our lead antibody clones are distinctly different
from existing antibodies reported to date in their binding geometry and footprints68, are highly inhibitory against SARS-CoV-2
and several variants of concerns, particularly the Delta variant
from the B.1.617 lineage. These antibodies thus expand the
repertoire of COVID-19 countermeasures against the SARS-CoV2 pathogen and its emerging and potentially more dangerous
variants.
Methods
Institutional approval. This study has received institutional regulatory approval. All
recombinant DNA (rDNA) and biosafety work were performed under the guidelines
of the Yale Environment, Health and Safety (EHS) Committee with approved protocols (Chen-15-45, 18-45, 20-18, 20-26; Xiong-17302; Wilen-18/16-2). All animal
work was performed under the guidelines of Yale University Institutional Animal
Care and Use Committee (IACUC) with approved protocols (Chen-2018-20068;
Chen-2020-20358; Wilen-2018-20198).
Animal immunization. Standard 28-day repetitive immunization protocol was
utilized for immunization. M. musculus (mice), 6–12 weeks old females, of C57BL/
6 J and BALB/c strains, were purchased from Jackson laboratory and used for
immunization. First, all mice are ear-marked and around 200 μl blood was taken as
a pre-immunization sample, where serum was collected from the blood by centrifugation (1000×g for 10 min). Two days later (day 0), for each mouse, 20 μg
SARS-CoV-2 RBD-his tag protein (Sino biological) in 100 μl PBS was mixed with
100 μl Complete Freund’s Adjuvant (CFA) with three-way stop Cock. The fully
emulsiﬁed mixture was subcutaneously injected into the back of each mouse. On
day 7, a second immunization was performed, where each mouse was injected
subcutaneously with 20 μg RBD-his tag protein fully emulsiﬁed with Incomplete
Freund’s Adjuvant (IFA). On day 13, around 50 μl of blood from each mouse was
obtained for serum preparation as ﬁrst bleeds. On day 14, a third immunization is
performed, where all the procedures were similar to the second immunization. On
day 20, second bleeds were taken. On day 21, the fourth immunization is performed, where all the procedures were similar to the second immunization. On day
24, each mouse receives 20 μg RBD-his tag protein in 200 μl PBS intraperitoneally
as ﬁnal immunization. On day 28, mice with strong serum conversion detected by
ELISA were sacriﬁced. Spleen, lymph nodes, and bone marrow were collected for B
cells isolation and puriﬁcation for single-cell BCR sequencing. Serums from pre,
ﬁrst, and second bleeds were subjected to ELISA for anti-RBD tilter determination.
Mouse B cell isolation and puriﬁcation. Primary B cells from the spleen, draining
lymph nodes, bone marrow of RBD-his tag protein immunized mice were isolated
and puriﬁed with mouse CD138 MicroBeads (Miltenyi Biotec, 130-098-257) following the standard protocol provided by the manufacturer. Spleens and draining
lymph nodes were homogenized gently. Bone marrows were fragmented, rinsed
with PBS containing 2% FBS, and ﬁltered with a 100 μm cell strainer (BD Falcon,
Heidelberg, Germany). The cell suspension was centrifuged for 5 min with 400 × g
at 4 °C. Erythrocytes were lysed brieﬂy using ACK lysis buffer (Lonza) with 1 mL
per spleen for 1–2 min before adding 10 mL PBS containing 2% FBS to restore isoosmolarity. The single-cell suspensions were ﬁltered through a 40 μm cell strainer
(BD Falcon, Heidelberg, Germany). CD138 positive B cells were isolated using
magnetic cell sorting by positive selection according to the manufacturer’s

instructions. Cell samples post-magnetic selection were counted and prepared for
single-cell BCR sequencing.
Single-cell BCR sequencing. The enriched CD138+ plasma cells and progenitor B
cells were loaded on a 10X Chromium Next GEM Chip G. The target cell number
was 10,000 cells per sample. Single-cell lysis and RNA ﬁrst-strand synthesis were
performed using Chromium Next GEM Single Cell 5′ Gel Bead V2 according to the
manufacturer’s protocol. The following RNA and V(D)J library preparation was
performed according to the manufacturer’s protocol (Chromium Next GEM Single
Cell V(D)J reagent kit, mouse BCR). The resulting VDJ-enriched libraries were
sequenced following the reading mode recommended by 10× Genomics. Sequencing was performed on a NovaSeq targeted for 10,000 reads/cell, with a total of 100
million reads.
Single-cell VDJ sequencing data analysis. Raw sequencing data were processed
using Cell Ranger v3.1.0 with default settings, aligning the reads to the GRCm38
mouse VDJ reference. Outputs from Cell Ranger were then visualized using the
Loupe V(D)J Browser for quality control assessment and to identify the top
enriched clonotypes. The consensus amino acid sequences for the top-ranked
heavy/light chain pairs in each sample were then extracted and codon-optimized
for human expression.
Plasmid construction. The cDNA sequences of the paired variable heavy and light
chain region of anti-RBD antibody clones were synthesized as gBlocks (IDT) and
cloned by the Gibson assembly (NEB) into human IgG1 heavy chain and light
chain expression plasmids, pFUSEss-CHIg-hG1(InvivoGen, pfusess-hchg1) and
pFUSE2ss-CLIg-hK (InvivoGen, pfuse2ss-hclk), respectively. pFUSEss-CHIg-hG1
plasmid is a cloning plasmid that expresses the constant region of the human IgG1
heavy chain and includes multiple cloning sites to enable cloning of the heavy
chain (CH) variable region. Parallelly, pFUSE2-CLIg-hK is a cloning plasmid that
expresses the constant region of the human kappa light chain and contains multiple cloning sites to enable cloning of the light chain variable region. For anti-RBD
antibody clones’ heavy chain plasmid cloning, gBlocks, containing cDNA sequence
of the variable region of the heavy chain of anti-RBD antibody clones and the
regions overlapping with corresponding ﬂanking sequences of EcoRI and NheI
restriction sites pFUSEss-CHIg-hG1, were ordered from IDT. pFUSEss-CHIg-hG1
were digested with EcoRI and NheI restriction enzyme (Thermo Fisher). These
synthesized gBlocks were cloned into gel-puriﬁed restriction enzyme digested
backbone by the Gibson assembly (NEB). For anti-RBD antibody clones’ light
chain plasmid cloning, gBlocks, containing cDNA sequence of the variable region
of the light chain of anti-RBD antibody clones and the regions overlapping with
corresponding ﬂanking sequences of EcoRI and BsiWI restriction sites pFUSE2ssCLIg-hK, were ordered from IDT. The gBlocks were then cloned into the
pFUSE2ss-CLIg-hK backbone, which was digested with EcoRI and BsiWI restriction enzyme (Thermo Fisher).
The bispeciﬁc antibody with the same Fab regions of clone 2 and clone 6 was
generated by using the CrossMab-KiH bispeciﬁc constructs69. The CrossMab-KiH
bispeciﬁc constructs were designed and generated based on pFUSEss-CHIg-hG1
and pFUSE2ss-CLIg-hK. The bispeciﬁc antibody consists of two hetero-half IgG1,
one is knob IgG1, and the other is hole IgG1 (Knob-in-Hole conformation). Four
plasmids were employed: pFUSE2ss-knobLight-hK, pFUSE2ss-knobheavy-hG1,
pFUSE2ss-HoleLight-hK, and pFUSE2ss-HoleHeavy-hG1. The pFUSE2ssknobLight-hK is pFUSE2ss-CLIg-hK with no further editing. The pFUSE2ssknobheavy-hG1 contains two knob mutations (T366W and S354C) in the CH3
region when compared with pFUSEss-CHIg-hG1. The gBlock (pPR024),
containing constant region of heavy chain with two knob mutations and the
regions overlapping with corresponding ﬂanking sequences of NsiI and NheI
restriction sites in pFUSEss-CHIg-hG1 was ordered from IDT and then cloned into
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NsiI and NheI restriction enzymes digested pFUSEss-CHIg-hG1 backbone by the
Gibson assembly (NEB). The pFUSE2ss-HoleLight-hK was generated by replacing
the constant region of light chain (CL) in pFUSE2ss-CLIg-hK with CH1 region of
heavy chain in pFUSEss-CHIg-hG1 vector. The CH1 region were PCR ampliﬁed
from pFUSEss-CHIg-hG1vectors with a forward primer (oPR81-F) and a reverse
primer (oPR82-R) containing regions overlapping with corresponding ﬂanking
sequences of the NcoI and NheI restriction sites in the pFUSE2ss-CLIg-hK. CH1
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PCR ampliﬁed fragments were gel-puriﬁed and cloned into restriction enzyme
digested pFUSE2ss-CLIg-hK by the Gibson assembly (NEB). The pFUSE2ssHoleHeavy-hG1 possesses three “hole” mutations (T366S, L368A, and Y407V) in
the CH3 region and a Y349C on the “hole” side to form a stabilizing disulﬁde
bridge. In addition, to get the correct association of the light chain and the cognate
heavy chain, the CH1 region in the pFUSE2ss-HoleHeavy-hG1 was exchanged with
the constant region of the light chain (CrossMab conformation). The gBlock
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Fig. 6 Generation, biophysical characterization, and functional testing of a humanized mAb clone. a Schematics of antibody humanization. b SDS-PAGE
of puriﬁed antibodies of humanized clones (Clone 13A) along with other clones, this experiment had been done for once. c Octet measurement of Clone
13A using the BLI assay. d (Top) Neutralization assay on Clone 2 (n = 3 biological replicates) and a Clone 13A (humanized Clone 2) (n = 3 biological
replicates) using WT SARS-CoV-2 Spike pseudotyped HIV-lentivirus carrying an EGFP reporter. (Bottom) Neutralization assay on Clone 2 (n = 2 biological
replicates) and a Clone 13A (humanized Clone 2) (n = 3 biological replicates) using B.1.617 variant SARS-CoV-2 Spike pseudotyped HIV-lentivirus carrying
an EGFP reporter. e In vitro neutralization of top mAb clones (Clones 2, 6, 13A) along with representative therapeutic antibody clones (RGEN 10933,
10987) against authentic SARS-CoV-2 WA1/2020 and B.1.617.2 (Delta) viruses in BL3 setting (n = 4 biological replicates). f, g Body weight curves of
humanized antibody Clone 13 A and placebo (isotype hIgG1) treated hACE2 transgenic mice under lethal challenges of authentic SARS-CoV-2 WA1.
f Spider curves of body weight changes of individual mouse plotted separated by group. g Mean ± SEM curves of body weight changes. (Clone 13 A, n = 9,
and hIgG1, n = 8 mice, respectively), Clone 13 A vs hIgG1: p = 0.0086. h Survival curves of Clone 13 A antibody and placebo (hIgG1) treated hACE2
transgenic mice under lethal challenges of authentic SARS-CoV-2 (the same experiment in f, g), Clone 13 A vs hIgG1: p < 0.0001, a two-sided statistical
test was used to assess statistical signiﬁcance. i, j Body weight curves of humanized antibody Clone 13 A and placebo (isotype hIgG1) treated hACE2
transgenic mice under lethal challenges of authentic SARS-CoV-2 Delta. i Spider curves of body weight changes of individual mouse plotted separated by
group. j Mean ± SEM curves of body weight changes. (Clone 13 A, n = 8, and hIgG1, n = 8 mice, respectively), Clone 13 A vs hIgG1: p < 0.0001. In this ﬁgure:
Data were shown as mean ± s.e.m. plus individual data points in dot plots. Statistics: Two-way ANOVA was used to assess statistical signiﬁcance for multigroup curve comparisons; Log-rank test was used to assess statistical signiﬁcance for survival curve comparisons; unless otherwise noted. The p values are
indicated in the plots. Source data and additional statistics for experiments are provided as a Source Data ﬁle.

(pPR023), containing cDNA sequence of the constant region of light chain, CH2
and CH3 with “hole” mutations, and regions overlapping with corresponding
ﬂanking sequences of NsiI and NheI restriction sites in pFUSEss-CHIg-hG1 was
ordered from IDT and cloned into NsiI and NheI restriction enzymes digested
pFUSEss-CHIg-hG1 backbone through Gibson assembly (NEB). All plasmids were
sequenced and Maxiprepped for subsequent experiments.
A list of oligos used for plasmid construction is provided in Supplemental
Table 1 in the Supplemental Information.
Cloning of SARS-CoV-2 spike variants. The construct of wild-type (WT) SARSCoV-2 ectodomain of spike trimer is a gift from Dr. Jason S. McLellan at the
University of Texas at Austin34. The recently emerged SARS-CoV-2 spike SA
variant B.1.3517 and Indian variant B.1.61711 was generated by standard cloning.
The pVP21-SA variant includes four mutations in the N-terminal domain (L18F,
D80A and D215G, R246I), three mutations at key residues in the RBD (N501Y,
E484K, and K417N), and one is in loop 2 (A701V). The pVP28-Indian variant
includes seven mutations in Spike G142D, E154K, L452R, E484Q, D614G, P681R,
and Q1071H. The pVP21-SA and pVP28-Indian were generated based on
pcDNA3.1-pSARS-CoV-2-S, which was derived by insertion of a synthetic human
codon-optimized cDNA (Geneart) encoding a WA1 SARS-CoV-2 S protein. For
pVP21-SA-variant, two gBlocks, contain mutations in SA variant regions overlapping with corresponding ﬂanking sequences of NheI and BsrGI restriction sites
pcDNA3.1-pSARA-CoV-2. The gBlocks were then cloned into the pcDNA3.1pSARA-CoV-2 backbone, digested with NheI and BsrGI restriction enzyme
(Thermo Fisher) through Gibson assembly. For pVP28-Indian, four gBlocks,
contains mutations in Indian variant regions overlapping with corresponding
ﬂanking sequences of NheI and BamHI restriction sites pcDNA3.1-pSARA-CoV-2.
The gBlocks were then cloned into the pcDNA3.1-pSARA-CoV-2 backbone,
digested with NheI and BamHI restriction enzyme (Thermo Fisher) through
Gibson assembly. For the HIV-1-based SARS-CoV-2 spike pseudotyped virus
generation, WT pcDNA3.1-pSARS-CoV-2-S, pVP21-SA-variant, and a pVP28Indian variant lacking the C-terminal 19 codons were employed. A pair of forward
and reverse primers were utilized to amplify fragments lacking the C-terminal 19
codons with the pVP21-SA variant and pVP28-Indian variant as templates separately. The ampliﬁed fragments were gel-puriﬁed and cloned into the pVP21-SA
variant backbone and pVP28-Indian variant backbone, digested with BbvCI
and BamHI.
Cell culture. HEK293FT (Thermo Fisher) and 293T-hACE2 (gifted from Dr.
Bieniasz’ lab) cell lines were cultured in the complete growth medium, Dulbecco’s
modiﬁed Eagle’s medium (DMEM; Thermo Fisher) supplemented with 10% Fetal
bovine serum (FBS, Hyclone),1% penicillin-streptomycin (Gibco) (D10 media for
short). Cells were typically passaged every 1–2 days at a split ratio of 1:2 or 1:4
when the conﬂuency reached 80%. Expi293FTM (Thermo Fisher) cells were cultured in Expi293™ Expression Medium (Thermo Fisher) in a 125-mL shaker ﬂask
in a 37 °C incubator with 8% CO2 on an orbital shaker rotating at 125 rpm. For
routine maintenance, Expi293FTM cells were grown to 3–5 × 106 cells/mL, then
split to 0.3–0.5 × 106 cells/mL every 3 days.
Expression and puriﬁcation of WT SARS-CoV-2 ectodomain of spike trimer.
The WT ectodomain of the SARS-CoV-2 spike trimer was expressed in Expi293F
cells. For 100 mL expression scale, 100 μg construct DNA was mixed with 400 μg
polyethylenimine in 10 mL Opti-MEM® I Reduced-Serum Medium (Thermo
Fisher) for 30 min, and then added into 90 mL Expi293F cells at a density of
2.5–3 × 106 cells/mL for incubation, shaking at 125 rpm in a 37 °C incubator with
8% CO2. After 5 days, the medium with the secreted protein was harvested and

loaded onto an ion-exchange column. Fractions containing the target protein was
pooled and further puriﬁed using a Ni-NTA afﬁnity column, followed by size
exclusion chromatography using a Superose 6 10/300 column (GE Healthcare) with
a buffer of 30 mM Tris, pH 8.0, 100 mM NaCl. The monodispersed peak containing the ectodomain of the spike trimer was pooled and concentrated for subsequent analysis.
Recombinant antibody generation. The top-ranked enriched IgG clones were
selected and cDNAs of a relative variable region of paired heavy- and light-chain
were codon-optimized and cloned separately into human IgG1 heavy chain and
light chain expression vectors, containing the human IgG1 constant regions (pFuse
plasmids). IgG1 antibodies were expressed in Expi293FTM cells. ExpiFectamine 293
transfection kit (Thermo Fisher) was utilized for heavy and light chain plasmids
transfection following the manufacturer’s instruction. After 5 days, the antibodycontaining supernatants were collected. A suitable amount of rProtein A Sepharose®
Fast Flow beads (Cytiva) was prewashed and added into supernatants. After overnight incubation at 4 °C, antibody-bound protein A beads were collected with PolyPrep® Chromatography Columns (BIO-RAD). After three times wash with DPBS,
mAbs were eluted with Fab elution buffer, then neutralized with Tris-HCl. Buffer
exchange was performed with Amicon Ultra-4 Centrifugal Filter (MilliporeSigma)
to keep mAbs in PBS for the following assays. The numbering of mAbs was based
on the order of mouse immunization and cloning. Clones 1–4 were mAbs chosen
from enriched clones from RBD-his tag protein immunized C57BL/6 J mice. Clone
5-11 were mAbs chosen from RBD-his tag protein immunized BALB/c mice.
Bispeciﬁc antibody generation. Clone 16 (Clone 6-KiH-Clone 2) bispeciﬁc
antibody is a human IgG1-like bispeciﬁc antibody, generated based on CrossMabKiH bispeciﬁc constructs, including pFUSE2ss-knobLight-hK, pFUSE2ss-knobheavy-hG1, pFUSE2ss-HoleLight-hK, and pFUSE2ss-HoleHeavy-hG1. The design
and generation of CrossMab-KiH bispeciﬁc constructs was described in the above
plasmid constructs parts. The variable region of the Clone 6 heavy chain was
cloned into pFUSE2ss-knobheavy-hG1 vector. The variable region of the Clone 6
light chain was cloned into pFUSE2ss-knobLight-hK vector. Clone 6-KiH-Clone 2
bispeciﬁc antibody was expressed in vitro in Expi293FTM cells by co-transfecting
four plasmids (Clone 6 knob heavy chain plasmid, Clone 6 knob light chain
plasmid, Clone 2 hole heavy chain plasmid, and Clone 2 hole light chain plasmid)
with ExpiFectamine 293 transfection kit (Thermo Fisher). The expression and
antibody puriﬁcation protocol was similar to the recombinant antibody expression
described above. The bispeciﬁc antibody was efﬁciently puriﬁed by using rProtein
A Sepharose Fast Flow antibody puriﬁcation resin (Cytiva, Cat:#17127901).
Antibody humanization. In order to humanize the antibody, we ﬁrst determine
the six CDR loops from murine variable domains by using the online free program
“IGBLAST” (https://www.ncbi.nlm.nih.gov/igblast/). Followed by applying the
CDR-grafting technique and grafting six CDR loops onto human acceptor frameworks. The framework template selection was based on sequence similarity to
close human germline sequence, as well as homology to clinically validated
germline sequences. Thereafter, we identify Vernier zone residues through CryoEM structure between Clone 2 and trimeric S protein of SARS-CoV-2 from parent
antibody (FR residues of Clone 2 within 5 Ǻ of trimeric S protein) and substitute
the key residues into the human acceptor framework of Clone 13 A.
ELISA
ELISA for anti-serum titer determination. The antibody tilters in sera from pre,
ﬁrst, and second bleeds were determined using direct coating ELISA. The 384-well
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ELISA plates (Corning) were coated with 3 μg/mL SARS-CoV-2 RBD-his tag
protein (Sino) in PBS at 4 °C overnight. After standard washing with PBST washing
buffer (phosphate-buffered saline containing 0.05% Tween 20), ELISA plates were
blocked with blocking buffer (2% bovine serum albumin dissolved in PBST and
ﬁltered) for 1 h at room temperature. Serial dilutions of pre-immune, ﬁrst, and
second immune anti-sera in blocking buffer were added into plates and for 1 h at
room temperature. Plates were washed and incubated with relative goat anti-mouse
IgG(H + L)/HRP (Thermo Fisher,1:5000) for 1 h at room temperature. Plates were
washed and developed using TMB reagents as substrates (Biolegend) following the
manufacturer’s recommended protocol. The reaction was stopped with a stop
solution (1 M H3PO4) and absorbance at 450 nm was recorded by a microplate
reader (Perkin Elmer).
ELISA for Anti-RBD antibody clones binding. SARS-CoV-2 RBD protein with 6 X
Histidine (Sino) was coated at 3 μg/ml in PBS on a 384-well microtiter plate
overnight at 4 °C. After standard washing with PBST and blocked with 2% (w/v)
solution of BSA in PBST to remove the nonspeciﬁc binding, puriﬁed anti-RBD
antibodies were diluted proportionally in PBST + 2% BSA and transferred to the
washed and blocked microtiter plates. After 1 h of incubation at RT, plates were
washed, and RBD-his tag protein-bound antibody was detected with goat antihuman IgG1 (H + L) with horseradish peroxidase (HRP) conjugated (Invitrogen,1:1000) The plates were washed and developed using TMB substrate solution
(Biolegend) according to manufacturer’s recommendation and absorbance at
450 nm was measured on a microplate reader after the reaction was stopped by
stop solution (1 M H3PO4).
Afﬁnity determination via bio-layer interferometry (BLI). Antibody binding
kinetics for anti-spike mAbs were evaluated by BLI on an Octet RED96e instrument (FortéBio) at room temperature. Two types of measurements were performed. (1) HIS1K biosensors (FortéBio) were ﬁrst loaded with his-tagged SARSCoV-2 RBD protein to a response of about 1 nm, followed by a 60 s baseline step in
the kinetic buffer (PBS, 0.02% Tween, pH 7.4). After that, the biosensors were
associated with indicated concentrations of the antibodies (from 50 to 0.78125 nM
with twofold dilutions, where the kinetic buffer was served as the negative control)
for 200 s, then dissociated in the kinetic buffer for 1000 s. (2) 25 ng/ul of Clone
13A-IgG1 antibodies were captured on an AHC biosensor (ForteBio). The baseline
was recorded for 60 s in a running buffer (PBS, 0.02% Tween 20, and 0.05% BSA,
pH 7.4). Afterward, the sensors were subjected to an association phase for 500 s in
wells containing RBD-his diluted in the buffer. In the dissociation step, the sensors
were immersed in the running buffer for 1000 s. The dissociation constants KD,
kinetic constants Kon and Koff, were calculated by using a 1:1 Langmuir binding
model with FortéBio data analysis software. Octet data were analyzed with Octet®
CFR software and Prism.
Afﬁnity measurement by surface plasmon resonance (SPR). Kinetics binding
measurement for anti-spike mAbs in this study was performed using a Biacore
T200 instrument (GE Healthcare). The system was ﬂushed with ﬁltered 1xHBSP + running buffer (0.01 M HEPES, 0.15 M NaCl, and 0.05%v/v Surfactant P20,
pH 7.4) and all steps were performed at 25 °C chip temperature.
Kinetics binding measurement on CM5 Chip (Series S sensor chip CM5). For kinetic
binding measurements, the CM5 chip surface was activated by injecting a solution
of EDC/NHS (GE Healthcare). Mouse anti-human IgG (Fc) mAb (25 μg/ml) was
immobilized on the sensor chip by amine coupling, followed by deactivation using
1 M ethanolamine. Afterward, anti-spike mAbs (0.1 μg/ml) were then ﬂowed over
and captured on anti-human IgG (Fc) mAb-coated surface. Subsequently, gradient
diluted his-tagged SARS-CoV-2 RBD solutions (1.875–30 nM, twofold serial
dilution) were injected individually in a single-cycle kinetic format without
regeneration (30 μl/min, association:180 s, dissociation:60 s). The binding data were
double referenced by blank cycle and reference ﬂow cell subtraction. Processed data
were ﬁtted by a 1:1 interaction model using Biacore T200 Evaluation Software 3.1.
Kinetics binding measurement on NTA Chip. For kinetic binding measurements,
the NTA chip was activated manually by loading a solution of NiCl2. Histidinelabeled SARS-CoV-2 RBD protein (0.075 μg/ml) was then ﬂowed over the chip and
captured on a nickel-coated surface. Subsequently, gradient diluted anti-spike
mAbs solutions (0.9875–15 nM, twofold serial dilution) were injected individually
in a single-cycle kinetic format without regeneration (30 μl/min, association:240 s,
dissociation:90 s). The binding data were double referenced by blank cycle and
reference ﬂow cell subtraction. Processed data were ﬁtted by a 1:1 interaction
model using Biacore T200 Evaluation Software 3.1.
SARS-CoV-2 pseudovirus reporter and neutralization assays. HIV-1 based
SARS-CoV-2 S pseudotyped virions were generated according to a previous
study70. Two plasmids are adopted to generate HIV-1 based SARS-CoV-2 S
pseudotyped virions. HIV-1 dual reporter vector expressing mCherry and luciferase (NL4-3 mCherry Luciferase, plasmid#44965) was purchased from Addgene.
Plasmid expression of a C-terminally truncated SARS-CoV-2 S protein (pSARSCoV-2Δ19) was obtained from Dr. Bieniasz’s lab. In order to generate HIV-1 based
14

SARS-CoV-2 S pseudotyped virions, 15×106 293FT cells were seeded in 150 mm
plates one day before in 20 ml D10 media. The following day, after the cell density
reaches 90%, the medium was discarded and replaced with a 13 mL serum-free
Opti-MEM medium. 20 μg NL4-3 mCherry Luciferase reporter plasmids and 15 μg
SARS-CoV-2 (pSARS-CoV-2Δ19) plasmids were mixed thoroughly in 225 μl
serum-free Opti-MEM medium. Then 100 μl Lipofectamine 2000 (Invitrogen) were
diluted in 225 μl serum-free Opti-MEM medium. Then the diluted plasmid mixture and Lipofectamine 2000 were mixed thoroughly and incubated for 10 min at
RT before adding into cells. After 6 h, the culture medium was changed back to the
completed growth medium, 20 mL for one 150 mm plate. At 48 h after transfection,
the 20 mL supernatant was harvested and ﬁltered through a 0.45-μm ﬁlter, aliquoted, and frozen in −80 °C.
Parallelly, the three plasmids-based HIV-1 pseudotyped virus systems were
utilized to generate (HIV-1/NanoLuc2AEGFP)-SARS-CoV-2 particles and (HIV-1/
NanoLuc2AEGFP)-SARS-CoV-2-SA variant particles. The reporter vector,
pCCNanoLuc2AEGFP, and HIV-1 structural/regulatory proteins
(pHIVNLGagPol) expression plasmid were gifts from Dr. Bieniasz’s lab70. Brieﬂy,
293 T cells were seeded in 150 mm plates and transfected with 21 µg
pHIVNLGagPol, 21 µg pCCNanoLuc2AEGFP, and 7.5 µg of a SARS-CoV-2 SΔ19
or SARS-CoV-2 SA SΔ19 plasmid utilizing 198 µl PEI. At 48 h after transfection,
the 20-ml supernatant was harvested and ﬁltered through a 0.45-μm ﬁlter, and
concentrated before aliquoted and frozen at −80 °C.
The pseudovirus neutralization assays were performed on 293T-hACE2 cell
line70. One day before, 293T-hACE2 cells were plated in a 96-well plate, 0.02 × 106
cells per well. The following day, serial dilution of monoclonal IgG from 40 μg/mL
(fourfold serial dilution using complete growth medium, 55 μL aliquots) were
mixed with the same volume of SARS-CoV-2 pseudovirus. The mixture was
incubated for 1 h at 37 °C incubators, supplied with 5% CO2. Then 100 μL of the
mixtures were added into 96-well plates with 293T-hACE2 cells. Plates were
incubated at 37 °C supplied with 5% CO2. Forty-eight hours later, 1 μL D-luciferin
reagent (Perkin Elmer, 33.3 mg/ml) was added to each well and incubated for
5 min. Luciferase activity was measured using a microplate spectrophotometer
(Perkin Elmer). The inhibition rate was calculated by comparing the OD value to
relative negative and positive control wells. For the three plasmids-based HIV-1
pseudotyped virus systems, 293 T cells were collected and the GFP + cells were
analyzed with Attune NxT Acoustic Focusing Cytometer (Thermo Fisher). The
50% inhibitory concentration (IC50) was calculated with a four-parameter logistic
regression using GraphPad Prism 8.0 (GraphPad Software Inc.).
Cell fusion assay
Vectors and plasmids. Plasmid encoding human ACE2 (hACE2) was obtained from
Addgene (hACE2; catalog #1786). The hACE2 2.6 kbp ORF was also blunt-cloned
into a third-generation HIV vector 3′ of the CMV promoter and 5′ of an IRESpuror cassette to generate pHIV-CMV-hACE2-IRES-Puro. It was inserted into a
piggybac transposon (Matt Wilson of Baylor College of Medicine, along with the
transposase plasmid pCMV-piggybac) that had been modiﬁed to encode a CMVIRES-bsdr cassette; the resultant plasmid was named pT-PB-SARS-CoV-2 SpikeIRES-Blasti. This too was inserted into piggybac transposon to make pT-PB-SARSCoV-2-UK Spike-IRES-Blasti.
Cell lines. The HOS cells were stably transduced with a third-generation HIV vector
encoding tat, along with eGFP, mRFP, and bleomycin resistance gene; they were
maintained in 200–400 μg/mL phleomycin (Invivogen) and were eGFP and mRFPpositive by ﬂow cytometry. hACE2 was subsequently introduced by VSV
G-mediated HIV-based transduction using pHIV-CMV-hACE2-IRES-Puro to
produce HOS-3734, which cell lines maintained in selection using 10 μg/mL puromycin (Sigma-Aldrich). TZMbl cells (#JC53BL-13) were obtained from the NIH
AIDS Reagent Program. TZMbl cells stably expressing wild-type S/UK variant S
were created by co-transfecting TZMbl cells with pT-PB-SARS-CoV-2- SpikeIRES-Blasti or pT-PB-SARS-CoV-2-UK Spike-IRES-Blasti, respectively, along with
pCMV-piggybac and resistant cells selected with 10 μg/mL blasticidin (Invivogen).
The control TZMbl cell line not expressing S was generated by co-transfecting
pCMV-piggybac with pT-pB-IRES-Blasti and selecting for blasticidin-resistant
TZMbl cells.
Cell fusion inhibition by monoclonal antibodies. Producer cells (TZMbl-wild-type
Spike/ Tzmbl-UK Spike) and target cells (HOS-3734) were generated as described
above. Ten thousand S-expressing cells (TZMbl-wild-type Spike/TZMbl-UK Spike)
in 100 µL of the medium in the absence of blasticidin were seeded in 96-well plates.
After 24 h, 70 μL of fourfold serially diluted antibody was added into producer cells
and incubated at 37 °C for 1 h. At that time 104 target cells (HOS-3734) in 50 μL
medium were then added to the producer cells, and after another 24 h cells were
lysed in 0.1 mL and RLU measured. Data were analyzed with nonlinear regression
using GraphPad Prism to determine the neutralization curve and the IC50 values
calculated.
In vitro neutralization against authentic SARS-CoV-2. SARS-CoV-1 (USAWA1/2020) was produced in Vero-E6 cells and tittered as described previously71.
SARS-CoV-2 neutralization was assessed by measuring cytotoxicity. About 5 × 105
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Vero-E6 cells were plated per well of a 96-well plate. The following day, serial
dilutions of antibodies were incubated with 2.5 × 103 plaque-forming units (PFU)
SARS-CoV-2 for 1 h at room temperature. SARS-CoV-2 neutralization was
assessed by measuring cytotoxicity. About 5 × 105 Vero-E6 cells were plated per
well of a 96-well plate. The following day, serial dilutions of antibodies were
incubated with 2.5 × 103 PFU SARS-CoV-2 for 1 h at room temperature. The
medium was then aspirated from the cells and replaced with 100 µl of the antibody/
virus mixture. After 72 h at 37 °C, 10 µl of CellTiter- Glo (Promega) was added per
well to measure cellular ATP concentrations. Relative luminescence units were
detected on Cytation5 (Biotek) plate reader. All conditions were normalized to
uninfected control. Each condition was done in triplicate in each of three independent experiments.
Focus reduction neutralization test. Serial dilutions of mAbs or sera were
incubated with 102 focus-forming units (FFU) of different strains or variants of
SARS-CoV-2 for 1 h at 37 °C. Antibody-virus complexes were added to VeroTMPRSS2 cell monolayers in 96-well plates and incubated at 37 °C for 1 h. Subsequently, cells were overlaid with 1% (w/v) methylcellulose in MEM supplemented
with 2% FBS. Plates were harvested 24 h later by removing overlays and ﬁxed with
4% PFA in PBS for 20 min at room temperature. Plates were washed and
sequentially incubated with an oligoclonal pool of SARS2-2, SARS2-11, SARS2-16,
SARS2-31, SARS2-38, SARS2-57, and SARS2-714,72. The anti-S antibodies and
HRP-conjugated goat anti-mouse IgG (Sigma, 12-349) in PBS supplemented with
0.1% saponin and 0.1% bovine serum albumin. SARS-CoV-2-infected cell foci were
visualized using TrueBlue peroxidase substrate (KPL) and quantitated on an
ImmunoSpot microanalyzer (Cellular Technologies).
In vivo efﬁcacy testing against authentic SARS-CoV-2. The efﬁcacy of mAbs
against replication-competent SARS-CoV-2 virus was evaluated in vivo, using both
a prophylactic setting where the animals were treated with mAb prior to viral
infection and a therapeutic setting where the animals were treated post-infection.
These experiments were performed in an animal BSL3 (ABSL3) facility. The
replication-competent SARS-CoV-2 (USA-WA1/2020) virus was produced in
Vero-E6 cells, and the titer was determined by plaque assay using WT Vero-E6.
The K18-hACE2 mice (B6.Cg-Tg(K18-ACE2)2Prlmn/J) were purchased from
the Jackson Laboratory and bred in-house using a trio breeding scheme. Mice were
sedated with isoﬂurane and infected via intranasal inoculation of 2000 PFU (20x
LD50) SARS-CoV-2 (USA-WA1/2020) virus administered in 50 uL of DPBS. Six to
eight-week-old K18-hACE2 littermate-controlled mice, mixed-gender (male/
female) mice were divided randomly into three groups and administered with
20 mg/kg (of mice body weight) Clone 2, Clone 6 or placebo/control, via
intraperitoneal (IP) injection. For a prophylactic experiment, the mAb drug/
placebo treatment was 24 h prior to the infection; for a therapeutic experiment, the
treatment was 18 h post-infection. The control for the prophylactic experiment was
DPBS, and the control for the therapeutic experiment was isotype control hIgG1,
where both controls are similar (no effect on disease progression). Survival, body
conditions, and weights of mice were monitored daily for 10 consecutive days.
In vivo efﬁcacy testing of humanized Clone 13A to authentic SARS-CoV-2
virus. Ten-12-week-old littermate-controlled female and male K18hAce2Tg+ mice
were pretreated with 20 mg/kg of either control hIgG1 (purchased from BioXCell)
or clone 13A mAb (produced by the Chen lab) administered IP in 300 uL of DPBS.
Twenty-four hours later, mice were anesthetized with isoﬂurane, and SARS-CoV-2
isolate USA-WA1/2020, or Delta variant (B.1.617.2), was inoculated intranasally at
a dose of 2 × 103 PFU/mouse (determined using wild-type Vero-E6) in 50 μL of
DPBS. Weights were obtained daily for 10 days following infection, and mice were
euthanized when morbid.
Fab generation. The Fab fragments of Clone 2 and Clone 6 were generated from
full-length IgGs of Clone 2 and Clone 6 using a commercial PierceTM Fab Preparation Kit (Thermo Fisher). All procedures were performed following the
manufacturer’s instructions. Brieﬂy, 2 mg of the whole IgGs of Clone 2 and Clone 6
were digested with immobilized papain at 37 °C for 4 h with rotation. Then protein
A beads were applied to bind the Fc fragments and undigested IgG. Then Fab
fragments were recovered in the ﬂow-through fraction, and further puriﬁed by size
exclusion chromatography using a Superdex 200 10/300 column (GE Healthcare)
in 30 mM Tris pH 8.0, 100 mM NaCl. The monodispersed peak of Fab fragments
was pooled and concentrated for subsequent analysis.
Cryo-EM sample preparation and data collection. The puriﬁed SARS-CoV-2
spike trimer at a ﬁnal concentration of 0.3 mg/mL (after mixture) was mixed with
Clone 2 or Clone 6 Fab at a molar ratio of 1:2 at 4 °C for 30 min. Then 3 μl of the
protein mixture was applied to a Quantifoil-Cu-2/1-3 C grid (Quantifoil) pretreated by glow-discharging at 15 mA for 1 min. The grid was blotted at 4 °C with
100% humidity and plunge-frozen in liquid ethane using FEI Vitrobot Mark IV
(Thermo Fisher). The grids were stored in liquid nitrogen until data collection.
Images were acquired on an FEI Titan Krios electron microscope (Thermo
Fisher) equipped with a Gatan K3 Summit direct detector in super-resolution
mode, at a calibrated magniﬁcation of 81,000× with the physical pixel size
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corresponding to 1.068 Å. Detailed data collection statistics for the Fab-spike
trimer complexes are shown in a Supplemental Table. Automated data collection
was performed using SerialEM 3.873.
Cryo-EM data processing. A total of 2655 and 1766 movie series were collected
for Clone 2 Fab-S trimer complex and Clone 6 Fab-S trimer complex, respectively.
The same data processing procedures were carried out for each complex as
described below. Motion correction of the micrographs was carried out using
RELION74 and contrast transfer function (CTF) estimation was calculated using
CTFFIND475. Particles were picked automatically by crYOLO76, followed by 2D
and 3D classiﬁcations without imposing symmetry. The 3D classes with different S
trimer conformations were then processed separately by consensus 3D reﬁnement
and CTF reﬁnement. Image processing and 3D reconstruction using cryoSPARC77
produced similar results. For each state of the Clone 6 Fab-S trimer complex,
multibody reﬁnements were then carried out in RELION by dividing the complex
into individual rigid bodies (three reﬁnements each with a rigid body containing a
unique Fab, RBD, and the N-terminal domain (NTD) of spike S1 subunit, and
another rigid body for the rest of the spike-ectodomain trimer). For each state of
the Clone 2 Fab-S trimer complex, local masked 3D classiﬁcation without image
alignment was performed focusing on one Fab-RBD region, and the best class of
particles was selected for consensus reﬁnement of the whole complex. Subsequently, multibody reﬁnement was performed as described above for the rigid body
containing the focused region. The 3D reconstruction of the other Fab-RBD
regions were obtained with the same procedure. The ﬁnal resolution of each
reconstruction was determined based on the Fourier shell correlation (FSC) cutoff
at 0.143 between the two half maps78. The ﬁnal map of each body was corrected for
K3 detector modulation and sharpened by a negative B-factor estimated by
RELION79, and then merged in Chimera for deposition. The local resolution
estimation of each cryo-EM map is calculated by RELION74. See also Supplementary Fig. 7 and Table 1.
Model building and reﬁnement. The structure of the ectodomain of SARS-CoV-2
spike trimer (PDB 6VSB) was used as an initial model and docked into the spike
trimer portion of the cryo-EM maps using Chimera80. The initial models of Clone
2 and Clone 6 Fabs were generated by homology modeling using SWISSMODEL81, and then docked into the Fab portions of the cryo-EM maps using
Chimera80. The initial models were subsequently manually rebuilt in COOT82,
followed by iterative cycles of reﬁnement in Refmac583 and PHENIX84. The ﬁnal
models with good geometry and ﬁt to the map were validated using the comprehensive cryo-EM validation tool implemented in PHENIX85. All structural ﬁgures
were generated using PyMol (http://www.pymol.org/) and ChimeraX80.
Homology modeling of SARS-CoV-2 variants. The structural models of SARSCoV-2 variants of RBD were generated by SWISS model81 using the wildtype / WA
RBD Cryo-EM structure as a template. The generated structures were aligned with
the wild-type RBD in complex with Clone 2, Clone 6, and/or other mAbs. The
cryo-EM structures and homology models were analyzed in Pymol.
Replication, randomization, blinding, and reagent validations. Sample size
determination was performed according to similar work in the ﬁeld, e.g., (Wang
et al. 2021 Nature).
Replicate experiments have been performed for key data shown in this study, as
detailed in methods and/or legends. Replicate experiments were successful where
applicable.
Biological or technical replicate samples were randomized where appropriate. In
animal experiments, mice were randomized by cage, sex, and littermates.
Experiments were not blinded. It is unnecessary for animal immunization for
antibody production to be blinded. Cryo-EM structure study can not be blinded.
Antibodies and dilutions. Commercial antibodies used for staining were the
following, with typical dilutions listed:
Mouse anti-Human lgGl Fe Secondary Antibody, HRP Thermo Fisher Cat#A10648, 1:2000
InVivoMAb human lgGl isotype control BioXcell Cat#BE0297.
Goat Anti-Mouse lgG H&L (HRP) Abcam ab6789, Abcam Cat#ab6789, 1:5000.
Recombinant monoclonal human lgGl antibody against Spike RBD lnvivogen
Cat#srbd-mabl
Custom antibodies were generated in this study, where dilutions were often
serial titrations (i.e., a number of dilutions as speciﬁed in each ﬁgure)
Anti-SARS-CoV-2 Spike mAbs:
Clone 1
Clone 2
Clone 3
Clone 4
Clone 5
Clone 6
Clone 7
Clone 8
Clone 9
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Clone 11
Clone 12
Clone 13
Clone 13A
Clone 16 (bispeciﬁc)
Commercial antibodies were validated by the vendors, and re-validated inhouse as appropriate. Custom antibodies were validated by speciﬁc
antibody–antigen interaction assays, such as ELISA. Isotype controls were used for
antibody validations.
Commercial antibody info and validation info where applicable:
https://www.thermoﬁsher.com/antibody/product/Mouse-anti-Human-IgG1Fc-Secondary-Antibody-clone-HP6069-Monoclonal/A-10648
https://bxcell.com/product/invivomab-human-igg1-isotype-control/
https://www.abcam.com/goat-mouse-igg-hl-hrp-ab6789.html
Eukaryotic cell lines. Cell line sources: Various, e.g., HEK293FT, Thermo Fisher
Cat#R70007
HEK293T-hACW2, Dr Bieniasz’s lab
Vero-E6, ATCC, Cat#CRL-1586TM
Expi293FTM, Thermo Fisher Cat#A14527
HOS-3734, ATCC, Cat#CRL-1543TM
TZMbl, Dr. Sutton’s lab.
Cell lines were authenticated by original vendors, and re-validated in the lab as
appropriate, by morphology and PCRs.
All cell lines tested negative for mycoplasma.
No commonly misidentiﬁed lines involved.
Animals and other organisms. Laboratory animals: M. musculus,
C57BL/6 J, Jackson laboratory, Cat#000664
B6.Cg-Tg(K18-ACE2)2Prlmn/J, Jackson laboratory, Cat#034860
BALB/c, Jackson laboratory, Cat#000651
Animals are maintained and bred in standard individualized cages with a
maximum of ﬁve mice per cage, at regular room temperature (65–75 °F, or
18–23 °C), 40–60% humidity, and a 12 h:12 h light cycle for breeding, and 13 h:11 h
or 14 h:10 h light cycle for experiments.
Wild animals: No wild animals were used in this study.
Field-collected samples: No ﬁeld-collected samples were used in this study.

All structural ﬁgures were generated using PyMol (v1.3) (online http://
www.pymol.org/) and ChimeraX (v1.2).
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.

Data availability
All data generated or analyzed during this study are included in this article, source data,
and Supplementary Information Files. Speciﬁcally, source data and statistics for nonhigh-throughput experiments are provided in a Supplementary Table excel ﬁle, Source
data are provided with this paper. High-throughput experiment data are provided as
processed quantiﬁcations in Supplemental Datasets. Genomic sequencing raw data have
been deposited to Gene Expression Omnibus (GEO) with the accession code
(GSE174635), The models of the mAb:Spike complexes have been deposited in the
wwPDB with accession codes: 3dSpike-Fab6,7MW2; 2dSpike-Fab6, 7MW3; 1dSpikeFab6, 7MW4; 2uSpike-Fab2, 7MW5; 3uSpike-Fab2, 7MW6. The cryo-EM maps of the
mAb:Spike complexes have been deposited in EMDB with accession codes: 3dSpikeFab6, EMD-24060; 2dSpike-Fab6, EMD-24061; 1dSpike-Fab6, EMD-24062; 2uSpikeFab2, EMD-24063; 3uSpike-Fab2, EMD-24064. Additional information related to this
study are available from the corresponding authors upon reasonable request. Source data
are provided with this paper.

Code availability
Codes that support the ﬁndings of this research are implementation of software publicly
available, as noted in the methods section.
Cellranger is available at (https://support.10xgenomics.com/single-cell-geneexpression/software/pipelines/latest/what-is-cell-ranger). Loupe Browser is available at
(https://www.10xgenomics.com/products/loupe-browser).
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